

Ms Renee Hutchens  
Adviser, ASX Listings Compliance (Sydney)  
20 Bridge Street,  
SYDNEY, NSW 2000

By email: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

**Request for Extension of Voluntary Suspension – Microba Life Sciences Ltd (ASX: MAP)**

Microba Life Sciences Ltd (ASX: MAP) (**Microba**), refers to the voluntary suspension of its securities granted on Friday, 5 June 2026.

Pursuant to ASX Listing Rule 17.2, Microba requests an extension to the voluntary suspension of its securities.

The voluntary suspension extension is requested in relation to a material capital raise (**Capital Raise**) and update on Microba's path to break even (**Break-even Update**) as referenced in the trading halt request dated 3 June 2026 and voluntary suspension request dated 5 June 2026.

Microba requires additional time to finalise the Capital Raise. Microba now expects to conclude these matters and to announce both the Capital Raise and the Break Even Update prior to the commencement of trading on Friday, 12 June 2026, and accordingly requests that the voluntary suspension be extended through to that date.

Microba considers that the lifting of the voluntary suspension ahead of that announcement being released would risk the market trading on an uninformed basis and without the benefit of an update to the path to break even plan, and could materially prejudice the orderly completion of the Capital Raise. The voluntary suspension extension is therefore requested to preserve a fair and informed market and to support the best available outcome for shareholders.

In accordance with ASX Listing Rule 17.2, Microba provides the following information:

- (a) Microba requests that the voluntary suspension remain in place until the earlier of commencement of trading on Friday, 12 June 2026 or such time that Microba makes an announcement to the market in relation to the Capital Raise and Break-even Update;
- (b) Microba is not aware of any reason why the extension of the voluntary suspension should not be granted; and
- (c) Microba is not aware of any other information necessary to inform the market about the extension of the voluntary suspension.

Yours sincerely,

**James Heath**

CFO & Company Secretary

*This announcement has been authorised for release by the Board of Directors.*



**JOIN MICROBA'S INTERACTIVE INVESTOR HUB**

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

[luke.reid@microba.com](mailto:luke.reid@microba.com)

**Investor / Media Relations**

[investor@microba.com](mailto:investor@microba.com)

<https://ir.microba.com/welcome>

**About Microba Life Sciences Limited**

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. [www.microba.com](http://www.microba.com)



**JOIN MICROBA'S INTERACTIVE INVESTOR HUB**

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621